Recent studies have demonstrated that the combination of a glutamine antagonist with anti-PD-1 therapy had a more obvious anti-tumor effect than did the anti-PD-1 therapy alone, and did not cause immune cell failure (Leone et al., 2019). This evidence concerns the gene PDCD1 and neoplasm.